Retatrutide vs Semaglutide
Side-by-side from the data we track independently: what each compound is, how it's typically dosed, what the community reports, and what it actually costs from live vendor offers. Full evidence lives on each peptide's page.
| Retatrutide | Semaglutide | |
|---|---|---|
| What it is | Triple hormone receptor agonist (GIP, GLP-1, glucagon). Phase 3 trials showing ~24% body weight reduction. | GLP-1 receptor agonist used for weight management and type 2 diabetes. Originally developed by Novo Nordisk. |
| Category | weight_loss | weight_loss |
| Typical dose | — | — |
| Half-life | ~144h | ~168h |
| Community reports | 481 firsthand reports (85.7% positive). Most reported: Weight loss & obesity management (302), Appetite & hunger regulation (158), Type 2 diabetes & blood sugar control (12). | 732 firsthand reports (85.8% positive). Most reported: Weight management & obesity (609), Other metabolic health benefits (72), Type 2 diabetes control (51). |
| Live pricing | From $0.41/mg across 282 vendors. Compare prices → | From $0.46/mg across 158 vendors. Compare prices → |
Common questions
Which is cheaper per mg, Retatrutide or Semaglutide?
On live captured offers, Retatrutide is currently cheaper per mg: from $0.41/mg across 282 vendors, versus Semaglutide from $0.46/mg across 158 vendors (USD-converted; prices change between sweeps).
Community counts reflect substantiated, linkable reports only. Prices are captured from vendor catalogues and change between sweeps. Research use only — nothing here is medical advice.